Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Global Forecast 2024-2030

[199 Pages Report] The Antiviral Therapeutics Market size was estimated at USD 75.53 billion in 2023 and expected to reach USD 82.01 billion in 2024, at a CAGR 8.28% to reach USD 131.82 billion by 2030.

Antiviral therapeutics are therapeutics specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. Antiviral drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics. Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Side effects associated with antiviral drugs high cost of development of medication hampers the growth of antiviral therapeutics. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth.

In the Americas, the antiviral therapeutics market is highly developing due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Innovative treatment regimens and a strong focus on research & development (R&D) have been catalyzed by significant investment from both the public and private sectors. European Union (EU) countries collectively represent a significant market, with overarching regulations governed by the European Medicines Agency (EMA). High standards of healthcare and a relatively wealthy population translate to a strong consumer need for the latest therapeutic options. The prevalence of universal health coverage across many EU countries means that purchasing behavior is largely determined by regulatory endorsements and national health care policies. The Middle East and Africa (MEA) presents a diverse market with varying degrees of access to healthcare. Wealthier nations in the Middle East have the financial resources to invest in modern therapeutics, while many African countries face significant barriers to access. Asia-Pacific region is rapidly expanding its presence in the antiviral therapeutics market, marked by increasing investment in pharmaceutical R&D and a large population base requiring medical treatment. The growing availability of local manufacturing and government initiatives in the region to improve healthcare access is driving market growth in Asia-Pacific.

The market dynamics represent an ever-changing landscape of the Antiviral Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Rising Prevalence of Viral Diseases Including HIV and Hepatitis
  • Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
  • Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
• Market Restraints
  • Relatively High Cost Associated with Antiviral Drug Treatment
• Market Opportunities
  • Advancements in Molecular Biology Promoting Drug Development
  • Improved Testing and Analysis of Viral Infections
• Market Challenges
  • Adverse Effects of Antiviral Drugs

• Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.

  Hepatitis antiviral drugs are designed to target hepatitis viruses such as HBV (Hepatitis B virus) and HCV (Hepatitis C virus). These drugs are essential for treating chronic hepatitis infections, which can lead to serious liver damage and hepatocellular carcinoma. Medications in this category include nucleoside/nucleotide analogs for HBV and direct-acting antivirals (DAAs) for HCV. Herpes antiviral drugs target the herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus (VZV), which causes chickenpox and shingles. These medications, such as acyclovir, valacyclovir, and famciclovir, are critical in managing outbreaks, reducing viral shedding, and decreasing the duration and severity of symptoms. HIV antiviral drugs are a combination of therapies known as antiretroviral therapy (ART), which help manage HIV infection. These drugs do not cure HIV but suppress the virus's replication, thereby improving the quality of life and reducing the risk of HIV transmission. Classes of ART drugs include reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and entry inhibitors. Influenza antiviral drugs are used to treat and prevent influenza. These drugs can lessen the symptoms and reduce the time someone is sick by 1-2 days. They can also reduce the severity of the disease and prevent complications such as pneumonia.

• Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV

  DNA polymerase inhibitors are a class of antiviral drugs designed to block the viral DNA polymerase enzyme, which is essential for viral DNA replication. These agents are particularly significant in the treatment of herpesviruses and certain hepadnaviruses, such as the hepatitis B virus. Their need-based preference is most pronounced among patients who require treatment for conditions including herpes simplex virus (HSV) infections and varicella-zoster virus (VZV), which causes chickenpox and shingles. Neuraminidase inhibitors target the neuraminidase enzyme, which is critical for the release and spread of the influenza virus. They are commonly prescribed for both the treatment and prevention of influenza A and B. The preference for these drugs increases during flu season and in pandemic preparedness scenarios, as they can significantly reduce the severity and duration of flu symptoms if administered promptly. Protease inhibitors disrupt the protease enzyme, which is essential for the maturation of many viruses, including HIV and hepatitis C virus (HCV). This class of drugs is a mainstay in the treatment of HIV/AIDS as part of highly active antiretroviral therapy (HAART) and has gained prominence in the treatment of HCV. Reverse transcriptase inhibitors are antiviral drugs that interfere with the reverse transcriptase enzyme, a key player in the replication of retroviruses, including HIV. Preferences for these medications are especially high in the management of HIV infections to prevent the virus from multiplying and to reduce the viral load to undetectable levels.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Antiviral Therapeutics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Antiviral Therapeutics Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of theAntiviral Therapeutics Market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The regulatory framework analysis for the Antiviral Therapeutics Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antiviral Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antiviral Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

• Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

  Gilead Sciences, Inc. and Assembly Biosciences, Inc. announced a comprehensive 12-year strategic partnership. This alliance is set to boost the development of groundbreaking antiviral agents, concentrating on Assembly Bio’s core competencies in combating herpesviruses, hepatitis B (HBV) and hepatitis D virus (HDV). [Published On: October 17, 2023]

• FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults

  The U.S. Food and Drug Administration has officially approved Paxlovid, an oral antiviral regimen consisting of nirmatrelvir and ritonavir tablets specifically designed for at-home administration to treat adult patients with mild-to-moderate COVID-19 who are at an increased risk of developing severe illness, which can lead to hospitalization or even fatality. This authorization marks Paxlovid as the first oral antiviral medication and the fourth therapeutic overall to receive FDA approval for combatting COVID-19 among adults. [Published On: May 25, 2023]

• Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program

  Shionogi & Co., Ltd updated their intensive clinical development initiatives for ensitrelvir, a pioneering oral medication designed to combat COVID-19. Known commercially as Xocova within Japan, ensitrelvir has secured emergency use authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for treating SARS-CoV-2 infections, based on favorable outcomes in the Asia-conducted Phase 3 segment of a combined Phase 2/3 clinical trial involving non-hospitalized subjects. As Shionogi continues to pursue global recognition, numerous Phase 3 clinical trials are being conducted to validate the safety profile and efficacy of ensitrelvir across diverse patient demographics. [Published On: February 15, 2023]

The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Eli Lilly and Company, Novartis AG, Johnson & Johnson Services Inc., Merck & Co., Inc., Syngene International Limited, Dr. Reddy’s Laboratories Ltd., Abbott Laboratories, Cocrystal Pharma, Inc., Atea Pharmaceuticals, Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Cipla Ltd., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Ltd., Pfizer Inc., Sanofi S.A., AbbVie Inc., Sun Pharmaceutical Industries Limited, Alkem Laboratories Limited, Gilead Sciences, Inc., Hetero Labs Limited, Viatris Inc., Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Aurobindo Pharma Limited, Venatorx Pharmaceuticals, Inc., and Zydus Lifesciences Limited.

This research report categorizes the Antiviral Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug
  • Hepatitis Antiviral Drug
  • Herpes Antiviral Drug
  • HIV Antiviral Drug
  • Influenza Antiviral Drug
• Therapy
  • DNA Polymerase Inhibitors
    • Non-nucleosides
    • Purine Nucleoside Analogues
    • Pyrimidine Nucleoside Analogues
  • Neuraminidase Inhibitors
  • Protease Inhibitors
  • Reverse Transcriptase Inhibitors
    • Nonnucleoside RTIs
    • Nucleoside RTIs
    • Nucleotide RTIs
• Distribution
  • Hospital Pharmacy
  • Independent Pharmacy & Drug Store
  • Online Pharmacy

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?